Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

LGC licenses first DNA test for response to schizophrenia treatment from the Institute of Psychiatry, King’s College London

09.11.2005


LGC, Europe’s leading independent analytical laboratory providing advanced chemical, biochemical and forensic analysis, has announced an exclusive agreement with King’s College London to offer the first pharmacogenetic screening service which will predict whether a patient with schizophrenia will respond positively to the antipsychotic drug clozapine. Developed following 13 years of research by Professor Robert Kerwin and Dr Maria Arranz from the Institute of Psychiatry at King’s, the test will help clinicians tailor the management of medication for schizophrenia to the needs of the patient.



Schizophrenia is considered the most chronic, debilitating and costly mental illness and affects between 1-2% of all populations. There is no permanent cure, but symptoms of the illness can be controlled by antipsychotic drugs. However, not all patients benefit from treatment and up to 40% of patients do not show a complete response - this is known as Treatment Resistant Schizophrenia (TRS).

Although clozapine is the only licensed drug with proven efficiency in the treatment of TRS its treatment can cause potentially serious side effects. It is therefore commonly only prescribed to patients when other medicines have failed. On average patients currently progress through four different antipsychotic medications over a period of five years before being treated with clozapine.


The test, which will be available to the clinical community from early January 2006, is a test based on a panel of single nucleotide polymorphisms (SNPs) that will be analysed using LGC’s proprietary fluorescent HyBeacons DNA probe technology. Dr Paul Debenham, Director of Life Sciences at LGC, said: "This new prediction test of treatment response to clozapine should prove to be an extremely valuable tool for clinicians, aiding them in their prescribing choice of antipsychotic drug for their patients. It will mean that clozapine can be prescribed much earlier on in the treatment of patients who are predicted to be responsive to the drug, thus reducing the suffering time of the patient and the associated cost of care. We are therefore delighted to be in a position to offer this kind of screening service to clinicians for the first time. This agreement is also great news for LGC, enabling us to build on our recent status as the first independent laboratory to become a member of the NHS Genetic Testing Network."

King’s Professor Robert Kerwin said: "This agreement follows 13 years of research at IoP into treatment for schizophrenia, working with more than 200 patients treated with clozapine. We are therefore delighted to be sharing the results of our research and to be working with LGC to be able to bring a viable example of personalised medicine into fruition."

Dr Paul Debenham and Professor Kerwin will be giving a presentation to discuss this new screening service at the ’Good Practice in Biological Investigation’ conference at Institute of Psychiatry, Denmark Hill campus, King’s College London, on Tuesday 8 November 2005. genetic services.

Wendy Taylor | alfa
Further information:
http://www.lgc.co.uk

More articles from Health and Medicine:

nachricht 3D images of cancer cells in the body: Medical physicists from Halle present new method
16.05.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Better equipped in the fight against lung cancer
16.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Explanation for puzzling quantum oscillations has been found

So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics

Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...

Im Focus: Dozens of binaries from Milky Way's globular clusters could be detectable by LISA

Next-generation gravitational wave detector in space will complement LIGO on Earth

The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...

Im Focus: Entangled atoms shine in unison

A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.

The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...

Im Focus: Computer-Designed Customized Regenerative Heart Valves

Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.

Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...

Im Focus: Light-induced superconductivity under high pressure

A team of scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg investigated optically-induced superconductivity in the alkali-doped fulleride K3C60under high external pressures. This study allowed, on one hand, to uniquely assess the nature of the transient state as a superconducting phase. In addition, it unveiled the possibility to induce superconductivity in K3C60 at temperatures far above the -170 degrees Celsius hypothesized previously, and rather all the way to room temperature. The paper by Cantaluppi et al has been published in Nature Physics.

Unlike ordinary metals, superconductors have the unique capability of transporting electrical currents without any loss. Nowadays, their technological...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Save the date: Forum European Neuroscience – 07-11 July 2018 in Berlin, Germany

02.05.2018 | Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

 
Latest News

Supersonic waves may help electronics beat the heat

18.05.2018 | Power and Electrical Engineering

Keeping a Close Eye on Ice Loss

18.05.2018 | Information Technology

CrowdWater: An App for Flood Research

18.05.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>